Moderna and Pfizer are each in the process of competing for federal contracts to build a national stockpile of mRNA vaccines targeted toward the new bird flu amid mounting concerns it may be spreading among humans.

Sources familiar with the discussions between the pharmaceutical giants and the Department of Health and Human Services report that the agency may agree to fund Moderna’s late-stage clinical trials of the bird flu vaccine to the tune of tens of millions of dollars.